6/10 Drugs.com - Clinical Trials

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Drugs.com - Clinical Trials Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data June 9, 2009 at 4:20 pm Multiple Single-Agent Responses in Patients with AML 14th Congress of the European Hematology Association BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported multiple objective responses at well-tolerated doses... Arete Therapeutics Reports Preclinical and Clinical Data at ADA June 9, 2009 at 4:12 pm -- Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes -- SOUTH SAN FRANCISCO, Calif.—June 9, 2009—Arete Therapeutics Inc. today announced the... NicOx Publishes Results of the ZEST Phase 2 Study for Naproxcinod June 9, 2009 at 4:12 pm June 9, 2009. Sophia Antipolis, France-NicOx S.A. (NYSE Euronext Paris: COX) today announced the full scientific publication of results from the ZEST phase 2 study for naproxcinod in the June issue of the Journal of Rheumatology1, an international... Transcept Pharmaceuticals Presents Data at SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies June 9, 2009 at 3:32 pm RICHMOND, Calif., June 09, 2009 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the... Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study June 9, 2009 at 3:02 pm NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced results from the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria... Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 June 9, 2009 at 3:02 pm SOUTH SAN FRANCISCO, Calif., June 09, 2009 /PRNewswire/ -- Arete Therapeutics Inc. today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an... The Lancet publishes direct comparison study between liraglutide and exenatide June 9, 2009 at 3:02 pm COPENHAGEN, June 9, 2009--Today, The Lancet published online the results of the LEAD™ 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with... VIAject Presentations at ADA Meeting Highlight Drug's Mechanism of Absorption and Microvascular Effects June 9, 2009 at 11:51 am Biodel Board Member Honored at ADA Awards Ceremony DANBURY, Conn.--(BUSINESS WIRE)--Jun 8, 2009 - Biodel, Inc. (Nasdaq:BIOD) today reported new information regarding the mechanism of action of VIAject® (injectable prandial insulin) and an update... StemCells, Inc. Announces Positive Phase I Batten Trial Results June 9, 2009 at 11:40 am Reports Evidence of Engraftment and Long-Term Survival of HuCNS-SC® Cells PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 8, 2009 - StemCells, Inc. (NASDAQ: STEM) announced today positive results from the first Phase I clinical trial of its proprietary... Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis June 9, 2009 at 11:30 am NESS ZIONA, Israel--(BUSINESS WIRE)--Jun 9, 2009 - Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a... ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease June 9, 2009 at 11:30 am IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) , today announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new,... Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit June 9, 2009 at 10:51 am FREMONT, Calif., June 9 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Bruce A. Molitoris, M.D., Director,... Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009 June 9, 2009 at 10:50 am Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO)... Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting June 9, 2009 at 10:44 am PARIS, June 08, 2009 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented... Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients June 9, 2009 at 10:44 am Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ:MITI) , a biopharmaceutical company developing novel, proprietary... Clinical Pharmacology Study With AZILECT (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity June 9, 2009 at 10:20 am  Study Indicated Rasagiline Selectivity for Inhibiting MAO-B at Maximum Approved Dose KANSAS CITY, Mo., June 9 /PRNewswire/ -- Teva Neuroscience, Inc. today presented results from a clinical pharmacology study in which AZILECT(R) (rasagiline... Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections June 9, 2009 at 10:07 am  Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2... Celator Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress June 9, 2009 at 10:04 am PRINCETON, N.J., June 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome... Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients June 9, 2009 at 9:54 am NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in... Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions June 9, 2009 at 9:45 am DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day treatment NEW ORLEANS, June 8 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented results from the first... Abbott's TRILIPIX (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets June 9, 2009 at 9:40 am Post-hoc analysis of two large clinical trials showed combination therapy helped more patients reach combined targets for HDL, triglycerides and LDL than the pre-determined therapy alone NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Abbott's... AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer June 9, 2009 at 9:29 am Quebec City, June 8, 2009 - Æterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results for the Company's European multi-center Phase 2 trial in... Afinitor Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial June 9, 2009 at 9:29 am  Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of... ConjuChem Reports Data on PC-DAC: Exendin-4 and PC-Insulin at 2009 American Diabetes Association Meeting June 9, 2009 at 9:28 am MONTREAL, June 8 /CNW/ - ConjuChem Biotechnologies, Inc. (TSX:CJB), today announced that it presented two posters at the 69th Scientific Sessions of the 2009 American Diabetes Association meeting held in New Orleans, LA on June 5-9, 2009. The first... Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association June 9, 2009 at 9:14 am  Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated... Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association June 9, 2009 at 9:05 am SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology... Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk June 9, 2009 at 8:42 am  - Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results - NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena... Orexigen Therapeutics Presents Additional NB-302 Contrave Data at American Diabetes Association (ADA) 69th Scientific Sessions June 9, 2009 at 8:41 am SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (NASDAQ:OREX) , a biopharmaceutical company focused on the treatment of obesity, today announced positive secondary findings from the first of four Phase 3 trials of its lead... Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins) June 9, 2009 at 8:31 am -Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia... Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily June 9, 2009 at 8:14 am Data Findings Published in June Issue of Circulation SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) and Eli Lilly and Company (NYSE:LLY) today announced the results of a pivotal... Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients June 9, 2009 at 8:13 am German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ:MITI)... Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines June 8, 2009 at 5:52 pm PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Jun 6, 2009 - Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, produced greater... Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies June 8, 2009 at 5:49 pm Partial Responses Demonstrated in 50 Percent of Evaluable Patients Treated in Phase 1 Trial Results Presented at the European Hematology Association Congress SEATTLE--(BUSINESS WIRE)--Jun 6, 2009 - Calistoga Pharmaceuticals, Inc., the leader in the... Halozyme's Phase 2 Insulin-PH20 Study Demonstrates Faster Insulin Absorption and Superior Glucose Control in Type 1 Diabetic Patients June 8, 2009 at 5:49 pm -- Insulin-PH20 combination significantly reduced post-meal blood glucose concentration relative to treatment target resulting in reduced hyperglycemia -- -- Significantly faster insulin absorption and greater peak insulin concentration observed... Dyax Presents Integrated Analysis of Phase 3 Data for DX-88 for Hereditary Angioedema June 8, 2009 at 4:14 pm - DX-88 Demonstrates Rapid and Sustained Relief of Symptoms in HAE Acute Attacks - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2009 - Dyax Corp. (Nasdaq:DYAX) announced presentation of an integrated analysis of the two DX-88 Phase 3 studies... Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma June 8, 2009 at 4:00 pm Data Show Longer Duration of Responses and Concordance between Investigator-Assessed and Independent Review of Responses BOTHELL, Wash.--(BUSINESS WIRE)--Jun 8, 2009 - Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I...   This email was sent to skripayura.drugsnews@blogger.com.  Create Your Account Don't want to receive this feed any longer? Unsubscribe here.